<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Crystal Amber Fund Limited — News on 6ix</title>
<link>https://6ix.com/company/crystal-amber-fund-limited</link>
<description>Latest news and press releases for Crystal Amber Fund Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 13:54:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/crystal-amber-fund-limited" rel="self" type="application/rss+xml" />
<item>
<title>Monthly Net Asset Value</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/monthly-net-asset-value</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/monthly-net-asset-value</guid>
<pubDate>Wed, 22 Apr 2026 13:54:00 GMT</pubDate>
<description>Monthly Net Asset Value.</description>
</item>
<item>
<title>Transaction in Own Shares and Total Voting Rights</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/transaction-in-own-shares-and-total-voting-rights-58</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/transaction-in-own-shares-and-total-voting-rights-58</guid>
<pubDate>Wed, 08 Apr 2026 09:51:00 GMT</pubDate>
<description>Crystal Amber Fund Limited has recommenced its share buyback programme with approximately £3 million remaining available, intending to repurchase ordinary shares up to this amount or 2,659,400 shares before its extraordinary general meeting on April 22, 2026. Purchases will only occur below the estimated net asset value per share when trading at a discount exceeding 20 percent. The company also announced the purchase of 50,000 ordinary shares at £1.01 on April 7, 2026, which will be cancelled, r</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/directorpdmr-shareholding-940</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/directorpdmr-shareholding-940</guid>
<pubDate>Thu, 02 Apr 2026 12:36:00 GMT</pubDate>
<description>Richard Bernstein, a Person Discharging Managerial Responsibilities for Crystal Amber Fund Limited, purchased 100,000 ordinary shares on March 31, 2026, for £1.0173 per share, totaling £101,727.46. Following this transaction, Bernstein directly holds 150,000 ordinary shares, representing approximately 0.25% of the company's total voting rights, and indirectly controls an additional 2,209,448 ordinary shares through Crystal Amber Asset Management Ltd, representing approximately 3.70% of the total</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/total-voting-rights-733</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/total-voting-rights-733</guid>
<pubDate>Tue, 31 Mar 2026 16:00:00 GMT</pubDate>
<description>Crystal Amber Fund Limited has announced its total voting rights as of March 31, 2026. The company has 77,077,262 ordinary shares in issue, representing 59,729,900 voting rights, with an additional 17,347,362 ordinary shares held in treasury. This information serves as the denominator for shareholders calculating their notification requirements under the Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Notice of results; update re strategy and manager</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/notice-of-results-update-re-strategy-and-manager</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/notice-of-results-update-re-strategy-and-manager</guid>
<pubDate>Mon, 16 Mar 2026 16:29:00 GMT</pubDate>
<description>Crystal Amber Fund Limited announced that its interim results for the six months ending 31 December 2025 will be released before 31 March 2026. The Board is progressing with the proposed change of strategy and investment manager, with further details and a circular for an Extraordinary General Meeting expected by the end of March.
Disclaimer*</description>
</item>
<item>
<title>Update on Morphic Medical Inc.</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/update-on-morphic-medical-inc</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/update-on-morphic-medical-inc</guid>
<pubDate>Mon, 16 Feb 2026 16:04:00 GMT</pubDate>
<description>Crystal Amber Fund Limited has invested an additional US$8 million, approximately £5.9 million, into Morphic Medical Inc. (MMI), bringing its total holding to 418,944,800 shares, representing 97.8% of MMI's issued share capital. MMI's Reset® device, which treats obesity and type 2 diabetes, has received European CE mark and UK regulatory approval, with distribution agreements in place for Spain, Belgium, Netherlands, Czech Republic, and the Middle East. Patient enrolment for the US Step-1 study </description>
</item>
<item>
<title>Replacement: Update and corrections regarding TVRs</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/replacement-update-and-corrections-regarding-tvrs</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/replacement-update-and-corrections-regarding-tvrs</guid>
<pubDate>Fri, 16 Jan 2026 12:18:00 GMT</pubDate>
<description>Crystal Amber Fund Limited has issued a correction regarding its total voting rights and shares held in treasury, stemming from an overstated purchase of 25,000 ordinary shares on December 17, 2025. The corrected total voting rights as of January 12, 2026, is now 60,393,500, with 16,683,762 shares held in treasury. The number of ordinary shares in issue remains 77,077,262 as of January 14, 2026.
Disclaimer*</description>
</item>
<item>
<title>Cancellation of treasury shares</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/cancellation-of-treasury-shares-39</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/cancellation-of-treasury-shares-39</guid>
<pubDate>Mon, 12 Jan 2026 17:46:00 GMT</pubDate>
<description>Crystal Amber Fund Limited announced the cancellation of 7,546,500 ordinary shares previously held in treasury, which were repurchased between March 27, 2025, and December 23, 2025. Following this cancellation, the company now holds 16,708,762 ordinary shares in treasury, resulting in 77,077,262 shares in issue and 60,368,500 voting rights. This change in the number of voting rights is important for shareholders to consider when determining their notification obligations under the Disclosure Gui</description>
</item>
<item>
<title>Share Buyback Programme</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/share-buyback-programme-91</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/share-buyback-programme-91</guid>
<pubDate>Wed, 03 Dec 2025 10:17:00 GMT</pubDate>
<description>Crystal Amber Fund Limited announced its intention to continue its share buyback program, aiming to repurchase up to £5,000,000 or 4,000,000 ordinary shares by March 15, 2026, with purchases only occurring when shares trade at a discount of over 20% to net asset value and at prices not exceeding 105% of the average market quotation. This initiative follows approximately £23.3 million returned to shareholders through buybacks since December 15, 2023, and the company has appointed Winterflood Secu</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/result-of-agm-939</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/result-of-agm-939</guid>
<pubDate>Tue, 02 Dec 2025 13:08:00 GMT</pubDate>
<description>Crystal Amber Fund Limited announced that all ordinary resolutions presented at its Annual General Meeting on December 2, 2025, were duly passed by poll. Resolution 1 received 99.87% of votes in favour, while Resolutions 2 through 8 all received approximately 93% of votes in favour, indicating strong shareholder support for the company's proposals.
Disclaimer*</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/holdings-in-company-1033</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/holdings-in-company-1033</guid>
<pubDate>Mon, 17 Nov 2025 17:59:00 GMT</pubDate>
<description>Merseyside Pension Fund has increased its voting rights in Crystal Amber Fund Limited to 21.15%, holding 12,938,214 shares, up from a previous holding of 20.30%. This change in the breakdown of voting rights was notified on November 17, 2025, and became effective on November 14, 2025. The fund is administered by Wirral Council as the Administering Authority.
Disclaimer*</description>
</item>
<item>
<title>Proposed change of strategy and investment manager</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/proposed-change-of-strategy-and-investment-manager</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/proposed-change-of-strategy-and-investment-manager</guid>
<pubDate>Fri, 14 Nov 2025 07:05:00 GMT</pubDate>
<description>Crystal Amber Fund Limited is proposing a significant strategic shift and a change in investment manager following discussions with major shareholders and the successful cash realisation of its De La Rue plc holding. The Fund's Net Asset Value is now heavily concentrated in its 97.7% stake in Morphic Medical Inc. (MMI), valued at 73.5% of NAV, with approximately £20.8 million in cash representing 18.2% of NAV. MMI has achieved CE mark approval for its Reset® device and is progressing with patien</description>
</item>
<item>
<title>Notice of AGM</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/notice-of-agm-492</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/notice-of-agm-492</guid>
<pubDate>Thu, 06 Nov 2025 07:00:00 GMT</pubDate>
<description>Notice of AGM.</description>
</item>
<item>
<title>Final Results</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/final-results-609</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/final-results-609</guid>
<pubDate>Fri, 17 Oct 2025 06:00:00 GMT</pubDate>
<description>Crystal Amber Fund Limited announced its final results for the year ended 30 June 2025, reporting an increase in Net Asset Value (NAV) per share by 2.6% to 178.39p. However, following share buybacks of £9.1 million and a loss for the year of £1.4 million, the NAV decreased from £126.7 million to £116.2 million. The company realized £40.7 million from De La Rue, with £18 million received shortly after year-end. Cash and cash equivalents at year-end were £10.94 million; had the De La Rue proceeds </description>
</item>
<item>
<title>Investor Presentation by Morphic Medical Inc</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/investor-presentation-by-morphic-medical-inc</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/investor-presentation-by-morphic-medical-inc</guid>
<pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
<description>Crystal Amber Fund Limited announced that Morphic Medical Inc. (MMI), in which the Fund holds a 96.7% stake of the issued share capital, will host a live investor presentation followed by a Q&A session on October 16, 2025, at 10:30 am. The presentation, hosted by MMI's CEO Mike Gutteridge, will include opening remarks from Crystal Amber's Chairman, Chris Waldron. The presentation is accessible to existing and potential shareholders via the Investor Meet Company platform, where questions can be s</description>
</item>
<item>
<title>Morphic Medical Inc. appoints new CFO</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/morphic-medical-inc-appoints-new-cfo</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/morphic-medical-inc-appoints-new-cfo</guid>
<pubDate>Mon, 15 Sep 2025 06:00:00 GMT</pubDate>
<description>Crystal Amber Fund is pleased with Morphic Medical's appointment of Jane Wright as its new Chief Financial Officer. Crystal Amber Fund owns 96.7% of the issued share capital of Morphic Medical. Wright's appointment follows the naming of Mike Gutteridge as CEO in July. RESET®, cleared for sale across key European markets after recent CE Mark certification, has demonstrated substantial benefits, with patients experiencing an average weight loss of 18.9% and improved blood sugar control, according </description>
</item>
<item>
<title>MMI's RESET achieves UK regulator registration</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/mmis-reset-achieves-uk-regulator-registration</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/mmis-reset-achieves-uk-regulator-registration</guid>
<pubDate>Wed, 27 Aug 2025 06:00:00 GMT</pubDate>
<description>Crystal Amber Fund Limited announced that Morphic Medical Inc. (MMI), in which the Fund owns 96.7% of the issued share capital, has achieved commercial registration from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for its RESET therapy. This follows the CE Mark designation received in July, allowing access to an estimated 93 million patients in Europe. Clinical studies showed patients lost an average of 19% of their total body weight within a year using RESET. A 2024</description>
</item>
<item>
<title>Morphic Medical Inc. appoints new Chief Executive</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/morphic-medical-inc-appoints-new-chief-executive</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/morphic-medical-inc-appoints-new-chief-executive</guid>
<pubDate>Tue, 05 Aug 2025 06:00:00 GMT</pubDate>
<description>Morphic Medical Inc. appoints new Chief Executive.</description>
</item>
<item>
<title>Fund update</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/fund-update-9</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/fund-update-9</guid>
<pubDate>Fri, 18 Jul 2025 06:00:00 GMT</pubDate>
<description>Fund update.</description>
</item>
<item>
<title>Morphic Medical Inc obtains regulatory approval</title>
<link>https://6ix.com/company/crystal-amber-fund-limited/news/morphic-medical-inc-obtains-regulatory-approval</link>
<guid isPermaLink="true">https://6ix.com/company/crystal-amber-fund-limited/news/morphic-medical-inc-obtains-regulatory-approval</guid>
<pubDate>Thu, 03 Jul 2025 06:00:00 GMT</pubDate>
<description>Morphic Medical Inc obtains regulatory approval.</description>
</item>
</channel>
</rss>